Asset profile
AZD9550
Peptide
Evidence outlook · results not reported
ASCEND (NCT06862791) · Obesity or Overweight
The lead study's design has limits that temper confidence (see the rationale below), and its results have not been reported. This tier describes the design, not an outcome.
ASCEND (NCT06862791): The study uses randomization, quadruple blinding, multiple placebo-controlled treatment groups, and includes 377 participants. Its primary endpoints are clinical weight-loss measures, but the results and whether the primary comparisons were met are not yet available, so the evidence cannot be rated as strong.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
66 competitors in this universe: 4 direct rivals (same mechanism and indication), 2 same-class, 60 same-indication; 53 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| AZD9550: this drug | Phase 2 | Peptide | GLP-1/glucagon receptor (dual) | ||
| Mazdutide | Phase 3 | Peptide | GLP-1/glucagon receptor (dual) | ||
| Survodutide | Phase 3 | Peptide | GLP-1/glucagon receptor (dual) | ||
| PB-718 | Phase 1/2 | Peptide | GLP-1/glucagon receptor (dual) | ||
| DA-1726 | Phase 1 | Peptide | GLP-1/glucagon receptor (dual) | ||
| Pemvidutide | Phase 3 | Peptide | GLP-1/glucagon receptor (dual) | ||
| OPK-88006 | Phase 1/2 | — | GLP-1/glucagon receptor (dual) | ||
| Liraglutide (Saxenda / Victoza) | Approved | Peptide | GLP-1 receptor | ||
| Naltrexone / Bupropion (Contrave) | Approved | Small molecule | Opioid receptor / dopamine (combination) | ||
| Orforglipron (Foundayo) | Approved | Small molecule | GLP-1 receptor | ||
| Orlistat (Xenical / Alli) | Approved | Small molecule | Pancreatic/gastric lipase | ||
| Phentermine / Topiramate (Qsymia) | Approved | Small molecule | Noradrenergic/anticonvulsant (combination) | ||
| Semaglutide (Wegovy / Ozempic / Rybelsus) | Approved | Peptide | GLP-1 receptor | ||
| Setmelanotide (Imcivree) | Approved | Peptide | MC4R | ||
| Tirzepatide (Zepbound / Mounjaro) | Approved | Peptide | GLP-1/GIP receptor (dual) | ||
| Aleniglipron | Phase 3 | Small molecule | GLP-1 receptor |
…and 51 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
October 2026 (1)
What to watch
2027 (3)
January 2027 (1)
What to watch
February 2027 (1)
What to watch
July 2027 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.